The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO-3 trial.
Anton CamajBimmer E ClaessenRoxana MehranMatias B YudiDavid PowerUsman BaberChristian HengstenbergThierry LefevreEric Van BelleGennaro GiustinoPaul GuedeneySabato SorrentinoChristian KupattJohn G WebbDavid Hildick-SmithHans U HinkEfthymios N DeliargyrisProdromos AnthopoulosSamin K SharmaAnnapoorna S KiniSamantha SartoriJaya ChandrasekharGeorge D DangasPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2020)
Patients undergoing TAVR and labeled high-risk by LES ≥ 18 or Heart Team assessment despite LES < 18 have comparable short-term outcomes. Assignment of high-risk status to over 50% of patients is attributable to Heart Team's clinical assessment.
Keyphrases
- transcatheter aortic valve replacement
- aortic stenosis
- aortic valve
- ejection fraction
- palliative care
- heart failure
- patients undergoing
- end stage renal disease
- atrial fibrillation
- chronic kidney disease
- quality improvement
- newly diagnosed
- clinical trial
- prognostic factors
- study protocol
- patient reported outcomes
- left ventricular
- coronary artery disease